artical in bio shares, page-5

Good analysis Sav.

Boil it down, and it comes to this:

Biotron developed BIT225 to be effective against HIV and HCV. Guided by expert advice, it has decided that HCV is a better market to pursue, at least initially, given the company's limited resources.

If the HCV market really was getting crowded out, as Bioshares is suggesting, why would Biotron persist with HCV trials when it has a ready-made alternative for clinical trials in HIV? The HIV cure/eradication space definitely isn't crowded out.

I reckon the company has a definite market niche or niches in mind, and probably likely partners. IMO, the design of this next HCV trial will have that very much in mind.

Spending a little cash to partner Biotron makes a lot of sense for big pharma if it bolsters the effectiveness and market share of drugs which have cost billions to develop/acquire.

GLA